Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 3/20 | 0.34 |
| ▸ | HTR5A | P47898 | 4/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21379060 | 1.00 | CHRM1 (0.34) | CHRM1HRH1PAK1TSPOHTR5A | |
| SCHEMBL2629043 | 0.94 | TSPO (0.37) | CHRM1HRH1PAK1TSPOHTR5A | |
| SCHEMBL21379004 | 0.84 | TSPO (0.35) | TSPOHTR5AAVPR1AOXTR | |
| SCHEMBL21397117 | 0.83 | HTR5A (0.39) | CHRM1HRH1PAK1HTR5ANR3C2 | |
| SCHEMBL29990699 | 0.83 | TSPO (0.34) | CHRM1HRH1TSPOHTR5AAVPR1A | |
| SCHEMBL21379279 | 0.83 | TSPO (0.34) | CHRM1HRH1TSPOHTR5AAVPR1A | |
| SCHEMBL21396613 | 0.83 | AVPR1A (0.37) | CHRM1TSPOAVPR1AOXTR | |
| SCHEMBL29989621 | 0.82 | PDE3B (0.46) | CHRM1HTR5AAVPR1AOXTR | |
| SCHEMBL20267114 | 0.82 | PDE3B (0.46) | CHRM1HTR5AAVPR1AOXTR | |
| SCHEMBL1496015 | 0.81 | TSPO (0.48) | TSPOHTR5AAVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2026-02-05 | — | — | US | disclosed |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | KINOXIS THERAPEUTICS PTY LTD. (AU) | 2025-11-04 | — | — | US | disclosed |
| US-20240245706-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-07-25 | — | — | US | disclosed |
| US-11890287-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-06 | — | — | US | disclosed |
| US-20220362261-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | THE UNIVERSITY OF SYDNEY (AU) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245706-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | CHRM1 1345/4885HRH1 2522/4885PAK1 2078/4885 |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | CHRM1 1345/4885HRH1 2522/4885PAK1 2078/4885 |
| US-11890287-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | CHRM1 1345/4885HRH1 2522/4885PAK1 2078/4885 |
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | SLC6A3, SLC6A4, SLC6A1 | CHRM1 156/4885HRH1 835/4885PAK1 3730/4885 |
| US-20220362261-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | SLC18A2, SLC6A3, CES2 | CHRM1 1345/4885HRH1 2522/4885PAK1 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.